The Expression Pattern of PDX-1, SHH, Patched and Gli-1 Is Associated with Pathological and Clinical Features in Human Pancreatic Cancer

Karl Quint, Sebastian Stintzing, Beate Alinger, Cornelia Hauser-Kronberger, Otto Dietze, Susanne Gahr, Eckhart G. Hahn, Matthias Ocker, Daniel Neureiter

Department of Medicine 1, University Hospital Erlangen, Erlangen, Germany; Institute of Pathology, Landeskliniken Salzburg, Salzburg, Austria

Key Words
Pancreatic carcinoma · Embryonic markers · Pancreas duodenum homeobox 1 · PDX-1 · Sonic hedgehog · SHH · Survival

Abstract

Background and Aims: Pancreatic cancer cells have been shown to possess stem-cell-like properties, especially by reactivating embryonic transcription factors involved in tissue differentiation. We therefore investigated if and to what extent developmental genes of the human pancreas are expressed in pancreatic ductal adenocarcinomas and precursor lesions, pancreatic intraepithelial neoplasia (PanIN), and if this correlates or predicts response to treatment and overall survival. Material and Methods: Invasive ductal adenocarcinomas of the pancreas [UICC pT3pN0 (n = 13) vs. pT3pN1 (n = 25)] and tumors after neoadjuvant chemotherapy [5-fluorouracil (FU)/folic-acid and gemcitabine; UICC ypN0 (n = 7) vs. ypN1 (n = 6)] resected between 1997 and 2003 were characterized histochemically and immunohistochemically [pancreas duodenum homeobox 1 (PDX-1), Sonic hedgehog protein (SHH), Patched (Ptc) and Gli-1]. Gene distribution was compared with morphological patterns of the pancreatic carcinoma and PanIN as well as with peritumorous reactions of normal pancreas. Results: The overall expression of PDX-1, SHH, Ptc and Gli-1 was low, but showed a distinctive and topographic linkage inside pancreatic carcinomas as well as inside PanINs. Additionally, a topographic and significant association of these markers with nodal status (PDX-1, Ptc, Gli-1), tumor size (PDX-1, Gli-1) and R status (PDX-1) was found. After stratification with the strongest outcome predictor, grading, survival analysis revealed that Ptc expression in grade 2 and PDX-1 expression in grade 3 carcinomas are independent survival factors. Conclusions: Markers of pancreas development are reexpressed in invasive ductal adenocarcinomas and their expression is essentially associated with general clinical and pathological features such as survival or nodal status.

Introduction

Pancreatic carcinoma is one of the most malignant carcinomas, accounting for 6% of cancer deaths in the Western world. Despite intensive research and recent improvements in patient outcome [1], overall survival remains very poor [2, 3]. A new approach to elucidate carcinogenesis is to understand organ embryology and to find a possible disarrangement of embryonic morpho-

K.Q., S.S., M.O. and D.N. contributed equally to this work.
genesis in the context of carcinogenesis [4, 5]. There is a large body of literature dealing with the expression of pancreas duodenum homeobox 1 (PDX-1) and Sonic hedgehog (SHH) proteins during gastrointestinal development in different species, and various knockout models emphasized the importance of the regulation of these embryological markers during morphogenesis [6–9]. The role of PDX-1 and of members of the hedgehog family such as SHH, the Patched (Ptc) receptor and the transcription factor Gli-1 was pointed out, especially in the pancreas, in the context of endocrine development, regeneration and possible recruitment of stem-cell-like precursor cells during chronic autoimmune and inflammatory destructive pancreatitis [10–14]. Recently, the role of stem cells and reexpression of stem-cell-like factors (e.g. PDX-1 and SHH) has been demonstrated during cancer development [15–17]. In this study, we examined if and to what extent and according to what distribution pattern PDX-1, SHH, Ptc and Gli-1 were expressed in human pancreatic ductal cancer (with and without nodal positivity) and pancreatic intraepithelial neoplasia (PanIN) specimens of a well-defined patient group. Furthermore, we investigated if their presence influences therapeutic responsiveness and overall survival times.

Materials and Methods

All samples were obtained from the archives of the Department of Pathology of the University of Erlangen-Nuremberg. All tissues were studied in an anonymous fashion, in accordance with the recommendations of the local ethics research committee. Furthermore, the analysis did not extend to examination of individual case records. Only patients with complete follow-up data (including standard risk factors [18, 19]) were considered. Surgical specimens from patients with invasive ductal adenocarcinoma of the pancreas (UICC pT3 pN0 or pT3pN1) who underwent tumor resection between 1998 and 2004 had been obtained during routine surgery and embedded in paraffin. To assess the role of embryonic differentiation markers on response to neoadjuvant chemotherapy (5-fluorouracil/folic acid and gemcitabine), another group of patients was investigated and analyzed as described.

Immunohistochemistry

Immunohistochemical staining procedures were applied as described before [20]. 5-μm sections were deparaffinized using graded alcohols. After microwave antigen retrieval (MW) (10 mmol/l citrate buffer, pH 6.0; 8 min at 560 W and 8 min at 800 W) or trypsin, the sections were incubated overnight using antibodies specific for PDX-1 (rabbit polyclonal antibody, dilution 1:250, MW, Chemicon, Temecula, Calif., USA), SHH (goat polyclonal antibody, 1:100, MW, Santa Cruz Biotechnology, Santa Cruz, Calif., USA), Ptc (goat polyclonal antibody, 1:100, trypsin, Santa Cruz Biotechnology), Gli-1 (goat polyclonal antibody, 1:200, MW, Santa Cruz Biotechnology), Ki-67 (mouse monoclonal antibody, 1:500, MW, Dako, Glostrup, Denmark) and p53 (mouse monoclonal antibody, 1:1,000, MW, Dako). Next, depending on the primary antibody, biotinylated rabbit-anti-goat or goat-anti-rabbit (Dako) antibodies were applied on the sections. Detection was done using Dako’s streptavidin-biotin complex and alkaline phosphatase system, following their user’s manual. The sections were developed using Fast Red (Sigma, Germany) or diaminobenzidine (DAB; Roche Molecular Biochemicals, Mannheim, Germany). Nuclei were counterstained with hematoxylin.

Morphological Pattern Analysis and Quantization of Stained Material

The stained sections were viewed by a blinded independent pathologist and representative images were taken from 4 high-power fields (400× magnification) in each section. Intensity of expression levels was characterized using the following scheme: negative (−), weak (+), moderate (++) and strong (+++), differing focal expression being indicated in round brackets. Additionally, the percentage of positive cells per high-power field was determined using ImageAccess Enterprise 5 software (Imagic Bildverarbeitung, Glattbrugg, Switzerland). For further statistical analysis, the calculated product of intensity and extensity was used. The distribution of PDX-1, SHH, Gli-1, and Ptc was compared with the morphological patterns of the pancreatic carcinoma (separately for tumor front and tumor center) and PanIN as well as with reactive response of normal pancreatic tissue [21, 22]. Because of the small size of PanIN lesions, only intensity measurement was statistically analyzed for PanIN. Although many heterogeneous target genes of PDX-1 and of members of the hedgehog family were described, most of them are associated with cell cycle or cell growth and death [23–25]. Therefore, we investigated the expression extensity of Ki-67 and p53 in the front and center areas of the tumor.

Statistical Analysis

For univariate analysis between different subgroups, the Mann-Whitney U test was used. Correlation coefficients were calculated according to Pearson and Kendall. Patient survival was estimated by the Kaplan-Meier method comparing the survival curves with the log-rank test; the correlation of sets of variables was determined in a multivariate analysis with the Cox proportional hazards model [26]. All tests were two-tailed. A p value of less than 0.05 was considered statistically significant. All statistical analyses were performed using SPSS 14 (SPSS Inc., Chicago, Ill., USA).

Results

Analysis of the General Pathologic Features

Patients’ main characteristics are listed in table 1. In short, the pT3pN0, pT3pN1, ypT1pN0 and ypT1pN1 groups consisted of 13, 25 and 6 patients, respectively. Patient populations in the nonchemotherapy groups (node-positive vs. node-negative) were adequately matched and did not show any statistically significant differences in gender, age, R status and tumor size. Grading was significantly higher in node-positive (G2/G3 =
10/15) compared to node-negative patients (G2/G3 = 10/3; \( \chi^2 \) test, \( p < 0.05 \)).

**Distribution Pattern of PDX-1- and Hedgehog-Expression Depending on Nodal Status and Preoperative Chemotherapy**

Overall, the mean expression rate of all investigated proteins was weak and the highest expression was observed for PDX-1 compared to proteins of the hedgehog signaling cascade. In detail, the expression level of PDX-1 in the tumor front was significantly lower in the pT3N0 sections than in pT3N1 sections; it was also significantly higher in the tumor center of pT3N0 than pT3N1 sections (Mann-Whitney U test, \( p < 0.05 \); table 2). SHH expression was low and statistically independent of nodal status or localization inside the tumor. Similarly, Ptc and Gli-1 expression was low but significantly higher at the tumor front (Ptc/Gli-1) and tumor center (Gli-1) in the pT3N1 sections than pT3N0 (see table 2). In the ypN0/ypN1 sections, the expression of all embryonic markers was significantly lower (negative to very low) compared to the nontreated group (Mann-Whitney U test, \( p < 0.05 \)) with the higher expression levels of PDX-1 comparable to those of the nontreated group. Interestingly, no signal of SHH, Ptc and Gli-1 was observed in the tumor center of ypN0 sections. Especially in the tumor center of grade 2 pancreatic carcinomas, Ptc expression was linked to dilated ductal tumor formation with focal coexpression of Gli-1 (fig. 2G, H, M, N) and with strong expression of p53 (fig. 2P–R). In adjacent non-tumorous tissue, upregulation of PDX-1 and SHH could be observed in areas of extended pancreatic fibrosis and atrophy, whereas in normal pancreas primarily endocrine cells express PDX-1 as well as SHH, Ptc or Gli-1 as internal control (fig. 1).

**Correlation Analysis of PDX-1 and Hedgehog Signaling Cascade with General Pathologic Features**

Correlation analysis revealed a significant negative correlation between PDX-1 expression at the tumor center and nodal status \( (r = -0.641, p < 0.001) \) and a significant positive correlation with tumor size \( (r = 0.499, p < 0.001) \) in patients not treated with chemotherapy. On the other
The tumor front and with p53 at the tumor center (r = 0.518, p = 0.04), whereas SHH and Ptc were usually (p > 0.05) linked to expression of Ki-67 and p53. Interestingly, besides a significant positive association of Ki67 at the tumor center with tumor size (r = 0.597, p = 0.03), other pathological features only tended to be positively linked to the expression of Ki-67 and p53.

### Correlation of Gene Expression Levels with Grade of PanINs

Overall, the expression of all proteins correlated significantly with the grade of PanINs (Spearman's correlation analysis, r > 0.98, p < 0.01). The expression levels were comparable with the invasive tumor compartments:

<table>
<thead>
<tr>
<th>Intensity/extensity and the calculated expression product of the markers at the tumor front (tf) and center (tc) in dependence of nodal status and pre-operative chemotherapy</th>
<th>pT3 pN0</th>
<th>pT3 pN1</th>
<th>ypNo</th>
<th>ypN1</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PDX-1</strong>&lt;sup&gt;1&lt;/sup&gt;</td>
<td>1.1 ± 0.3/13.1 ± 0.9</td>
<td>1.4 ± 0.5/13.6 ± 1.0</td>
<td>0.6 ± 0.5/6.6 ± 1.5&lt;sup&gt;*&lt;/sup&gt;</td>
<td>1.3 ± 0.5/13.0 ± 1.5 &lt;sup&gt;*&lt;/sup&gt;</td>
</tr>
<tr>
<td>TF</td>
<td>1.47 ± 5.5</td>
<td>20.3 ± 7.8</td>
<td>4.1 ± 3.8</td>
<td>18.3 ± 10.1</td>
</tr>
<tr>
<td>TC</td>
<td>2.1 ± 0.6/15.6 ± 0.8&lt;sup&gt;*&lt;/sup&gt;</td>
<td>1.3 ± 0.4/13.4 ± 1.1</td>
<td>1.4 ± 0.5/13.8 ± 1.1</td>
<td>1.3 ± 0.5/13.5 ± 1.3</td>
</tr>
<tr>
<td>33.4 ± 11.2&lt;sup&gt;*&lt;/sup&gt;</td>
<td>18.1 ± 7.7</td>
<td>19.8 ± 9.3</td>
<td>n.d./n.d.</td>
<td>n.d./n.d.</td>
</tr>
<tr>
<td><strong>SHH</strong></td>
<td>0.6 ± 0.5/8.3 ± 1.0</td>
<td>0.5 ± 0.5/6.8 ± 1.5</td>
<td>0.5 ± 0.7/6.2 ± 2.0</td>
<td>0.6 ± 0.5/6.6 ± 2.0</td>
</tr>
<tr>
<td>TF</td>
<td>5.1 ± 4.3</td>
<td>3.7 ± 3.6</td>
<td>4.1 ± 6.6</td>
<td>3.9 ± 3.9</td>
</tr>
<tr>
<td>TC</td>
<td>0.2 ± 0.4/5.1 ± 1.1</td>
<td>0.3 ± 0.4/3.8 ± 0.8</td>
<td>n.d./n.d.</td>
<td>n.d./n.d.</td>
</tr>
<tr>
<td>1.2 ± 2.1</td>
<td>1.1 ± 1.8</td>
<td>n.c.</td>
<td>n.c.</td>
<td></td>
</tr>
<tr>
<td><strong>Ptc</strong></td>
<td>0.4 ± 0.5/4.1 ± 0.8&lt;sup&gt;*&lt;/sup&gt;</td>
<td>0.9 ± 0.2/7.6 ± 1.3</td>
<td>0.6 ± 0.5/3.3 ± 0.5</td>
<td>0.3 ± 0.5/3.2 ± 0.8</td>
</tr>
<tr>
<td>TF</td>
<td>1.7 ± 2.1</td>
<td>7.0 ± 2.4</td>
<td>1.9 ± 1.8</td>
<td>0.9 ± 1.7</td>
</tr>
<tr>
<td>TC</td>
<td>0.5 ± 0.5/5.2 ± 1.2</td>
<td>0.7 ± 0.4/5.8 ± 0.5</td>
<td>n.d./n.d.</td>
<td>n.d./n.d.</td>
</tr>
<tr>
<td>2.7 ± 2.7</td>
<td>4.1 ± 2.7</td>
<td>n.c.</td>
<td>n.c.</td>
<td></td>
</tr>
<tr>
<td><strong>Gli-1</strong></td>
<td>0.1 ± 0.3/2.2 ± 0.5&lt;sup&gt;*&lt;/sup&gt;</td>
<td>0.8 ± 0.3/6.9 ± 0.7</td>
<td>n.d./n.d.</td>
<td>n.d./n.d.</td>
</tr>
<tr>
<td>TF</td>
<td>0.2 ± 0.6</td>
<td>5.9 ± 2.6</td>
<td>n.c.</td>
<td>0.9 ± 1.6</td>
</tr>
<tr>
<td>TC</td>
<td>0.2 ± 0.4/5.9 ± 1.0&lt;sup&gt;*&lt;/sup&gt;</td>
<td>0.6 ± 0.4/5.3 ± 0.6</td>
<td>n.d./n.d.</td>
<td>n.d./n.d.</td>
</tr>
<tr>
<td>1.2 ± 2.4&lt;sup&gt;*&lt;/sup&gt;</td>
<td>3.3 ± 2.7</td>
<td>n.c.</td>
<td>n.c.</td>
<td></td>
</tr>
<tr>
<td><strong>Ki-67&lt;sup&gt;4&lt;/sup&gt;</strong></td>
<td>27.8 ± 8.5</td>
<td>27.5 ± 7.4</td>
<td>13.1 ± 3.6</td>
<td>14.2 ± 2.6</td>
</tr>
<tr>
<td>TF</td>
<td>20.1 ± 5.7</td>
<td>20.6 ± 7.8</td>
<td>9.1 ± 3.1</td>
<td>8.3 ± 3.2</td>
</tr>
<tr>
<td>TC</td>
<td>20.6 ± 11.8</td>
<td>23. ± 16.8</td>
<td>8.3 ± 3.5</td>
<td>7.3 ± 2.0</td>
</tr>
<tr>
<td>16.0 ± 10.3</td>
<td>12.8 ± 7.6</td>
<td>3.6 ± 0.5</td>
<td>4.1 ± 2.2</td>
<td></td>
</tr>
<tr>
<td><strong>p53&lt;sup&gt;4&lt;/sup&gt;</strong></td>
<td>20.6 ± 11.8</td>
<td>23. ± 16.8</td>
<td>8.3 ± 3.5</td>
<td>7.3 ± 2.0</td>
</tr>
<tr>
<td>TF</td>
<td>16.0 ± 10.3</td>
<td>12.8 ± 7.6</td>
<td>3.6 ± 0.5</td>
<td>4.1 ± 2.2</td>
</tr>
<tr>
<td>TC</td>
<td>16.0 ± 10.3</td>
<td>12.8 ± 7.6</td>
<td>3.6 ± 0.5</td>
<td>4.1 ± 2.2</td>
</tr>
</tbody>
</table>

<sup>*</sup>p < 0.05. n.d. = Not detected; n.c. = not calculated.

1 Semiquantitative evaluation of the stainings: negative (0), weak (+ or 1), moderate (++ or 2) and strong (+++) or 3).
2 Quantitative evaluation of the stainings (mean % of all cancer cells at 4 different high-power fields per tumour specimen).
3 Calculated expression product: intensity × extensity.
4 For Ki-67 and p53 the extensity was measured by mean % of all cancer cells at 4 different high-power fields per tumour specimen.
**Table:**

<table>
<thead>
<tr>
<th></th>
<th>pT3pN0 Front</th>
<th>pT3pN0 Center</th>
<th>pT3pN1 Front</th>
<th>pT3pN1 Center</th>
<th>Control</th>
</tr>
</thead>
<tbody>
<tr>
<td>PDX-1</td>
<td><img src="image1.png" alt="Image" /></td>
<td><img src="image2.png" alt="Image" /></td>
<td><img src="image3.png" alt="Image" /></td>
<td><img src="image4.png" alt="Image" /></td>
<td><img src="image5.png" alt="Image" /></td>
</tr>
<tr>
<td>SHH</td>
<td><img src="image6.png" alt="Image" /></td>
<td><img src="image7.png" alt="Image" /></td>
<td><img src="image8.png" alt="Image" /></td>
<td><img src="image9.png" alt="Image" /></td>
<td><img src="image10.png" alt="Image" /></td>
</tr>
<tr>
<td>Ptc</td>
<td><img src="image11.png" alt="Image" /></td>
<td><img src="image12.png" alt="Image" /></td>
<td><img src="image13.png" alt="Image" /></td>
<td><img src="image14.png" alt="Image" /></td>
<td><img src="image15.png" alt="Image" /></td>
</tr>
<tr>
<td>Gli-1</td>
<td><img src="image16.png" alt="Image" /></td>
<td><img src="image17.png" alt="Image" /></td>
<td><img src="image18.png" alt="Image" /></td>
<td><img src="image19.png" alt="Image" /></td>
<td><img src="image20.png" alt="Image" /></td>
</tr>
</tbody>
</table>

**Fig. 1.** Typical immunohistochemical patterns of PDX-1, SHH, Ptc and Gli-1 in pancreatic cancer in dependence of nodal status: overall, independent of the nodal status, higher expression of PDX-1 was observed compared to all other markers of the hedgehog signaling pathway. PDX-1 was mainly detected in ductal tumor formations in the tumor center. The expression of SHH was low and predominantly located in disseminated ductal formations or single tumor cells at the tumor front (see arrows). Ptc and Gli-1 were mainly found in single tumor cells (see arrows), especially of node-positive cases. As an internal control, endocrine cells inside the islets of Langerhans of normal pancreas showed typical expression of PDX-1, SHH, Ptc and Gli-1, focally with nuclear expression (see arrows) (magnification of all figures: 400×).

**Fig. 2.** Representative immunohistochemical expression pattern of PDX-1, Ptc and Gli-1 in consecutive specimens depending on localization and grading of pancreatic carcinoma. Typical expression of PDX-1 at the tumor front (B, 200×) in a G3 pancreas carcinoma specimen with predominant solid tumor formations (square) (A, HE, 12.5×). PDX-1 was detected inside and around ductal tumor structures with mainly cytoplasmic but focally intranuclear localization (B, arrows). The corresponding tumor area revealed enhanced proliferative activity using immunohistochemistry for Ki-67 (C, 200×). Inside indicated areas of a G2/G3 pancreas carcinoma specimen with ductal/solid tumor formations at the tumor front (D, square, HE, 12.5×) and tumor center (D, dotted square, HE, 12.5×) Ptc and Gli-1 were expressed only very sparsely at the tumor front in single cells (E, Ptc, arrows, 200×; F, Gli-1, arrow, 200×) and enhanced at the tumor center especially inside dilated tumor ductal structures (G, Ptc, 200×; H, Gli-1, 200×). Representative areas of a G2 pancreas carcinoma specimen at the tumor front (I, square, HE, 12.5×) and tumor center (I, dotted square, HE, 12.5×) in comparison to the expression of Ptc (J, tumor front, 200×; M, tumor center, 200×), Gli-1 (K, tumor front, 200×; N, tumor center, 200×) and PDX-1 (L, tumor front, 200×; O, tumor center, 200×). Ptc and Gli-1 were predominantly expressed at the tumor center (M, N) whereas PDX-1 was found at the tumor front, predominantly in association with ductal tumor formations (L). Expression of Ptc (P, 400×) and Gli-1 (Q, 400×, arrows) in typical ductal tumor formation at the tumor center (of I, dotted square) was associated with strong expression of p53 (R, 400×).
Embryonic Differentiation Markers in Human Pancreatic Cancer

Pancreatologia 2009;9:116–126

121
The expression of PDX-1 was significantly higher than those of the members of the hedgehog signaling cascade ($\chi^2$ test, $p < 0.05$). In detail, expression levels of PDX-1 continuously increased from low expression in PanIN-1A and -1B to moderate in PanIN-2 and high in PanIN-3 lesions (fig. 3) with no significant dependence on the nodal state ($\chi^2$ test, $p > 0.05$). No expression of SHH, Ptc and Gli-1 was found in PanIN-1A and -1B lesions, whereas low expression was seen in lesions of PanIN-2 (SHH: 0.24 ± 0.43, Ptc: 0.22 ± 0.42 and Gli 1: 0.06 ± 0.25) and PanIN-3 (SHH: 0.24 ± 0.49, Ptc: 0.19 ± 0.40 and Gli-1: 0.16 ± 0.37). No significant difference was found between the node-positive and the node-negative group ($\chi^2$ test, $p > 0.05$). A correlation analysis of protein expression in PanINs with general pathologic findings as well as protein expression in the invasive compartments of the carcinoma revealed a positive association with protein expression in the invasive carcinoma independent of the location, but the association did not reach significance.

**Survival Time Analysis**

The mean expression rate of PDX-1, Shh, Ptc and Gli-1 as well as of Ki-67 and p53 in tumor center and front was calculated for further time-dependent statistical analysis and divided into low and high expression rates according to mean expression level. Age, sex, grading, nodal status (N0 versus N1), tumor size, R status and preoperative chemotherapy were used for the Cox-regression analysis. Only grading was identified as a factor significantly influencing survival (Wald $\chi^2_{d.f. = 1} = 3.987$, hazard ratio 2.645, confidence interval: 0.916–7.641, $p = 0.05$) (fig. 4A). The expression patterns of the analyzed proteins did not additionally influence patient survival. Therefore, a stratification of the patients according to tumor grading was done. Using this model, the Kaplan-Meier analysis identified the expression of PDX-1 at the tumor front in the grade 3 subgroup and Ptc expression in the tumor center of the grade 2 subgroup as predictive prognostic factors. PDX-1 expression at the tumor front had a significant negative influence on survival in grade 3 pancreatic carcinomas (Logistic Rank Test (Mantel Cox) $p = 0.05$; fig. 4C), whereas higher expression of Ptc at the tumor center was associated with better outcome in grade 2 pancreatic carcinomas (Logistic Rank Test (Mantel Cox) $p = 0.03$; fig. 4B, C). All additionally performed sum scores of PDX-1, SHH, Ptc and Gli-1 as well as of Ki-67 and p53 had no significant impact on the survival time. This was also evident for the expression of these proteins in PanINs also in circumstances of recoding in low and high expression.

**Discussion**

The main findings of our investigation are summarized as follows: (1) PDX-1 as well as proteins of the hedgehog signaling cascade such as SHH, Ptc and Gli-1 were found in low to moderate amounts in pancreatic carcinomas. (2) Additionally, these markers were found in linear (PDX-1) and nonlinear (hedgehog) expression patterns in precancerous lesions of PanINs. (3) The expression of these embryological markers was clearly associated with pathological and clinical features (nodal status, tumor size and pre-operative treatment). (4) Finally, classical grading influenced survival of the patients with pancreas carcinoma. Using statistical stratification with grading, single protein expression of PDX-1 or Ptc could be identified as a possible predictive survival marker.

Our study complemented what was already known about the expression of embryonic markers like PDX-1, SHH, Ptc and Gli-1 in pancreatic cancer and its precursor lesions [15–17]. We have shown the exact expression levels at different localizations within the tumor, i.e. enhanced expression of these markers in ductal tumor formations (assessed separately for tumor front and center) and in adjacent fibrotic and atrophic tissue. Mainly PDX-1 and to a lower extent SHH, Ptc and Gli-1 were detected in the human pancreatic carcinoma specimens. In contrast to the linear PDX-1 expression inside PanINs, hedgehog family members showed a stepwise black-or-
white expression pattern comparable to findings in intraductal papillary mucinous tumors, which are putative pancreatic cancer precursor lesions, too [27]. This indicates that embryonic markers of morphogenesis are associated with the grade and progression of PanINs similarly to classical markers of proliferation and differentiation [28]. Interestingly, the expression pattern was heterogeneous in invasive carcinomas: we found a higher expression of hedgehog members (especially Ptc) at the tumor front and in the center in nontreated nodal-positive cases than in nontreated nodal-negative cases. In contrast, the distribution of PDX-1 was the same as that of the hedgehog proteins at the tumor front but differed in the tumor center. Although Gli proteins are known nuclear transcription factors, they are also part of the cytoplasmic signal transduction pathway of SHH via its membranous receptor Ptc and the Smoothened (SMO) regulator [29], which is in line with our results showing (predominant) cytoplasmic and nuclear expression of Gli-1. While the regulation of cytoplasmic to nucleus shuttling is well described for the Drosophila homologue of Gli, cubitus interruptus (Ci), this mechanism is not completely understood in vertebrates [30]. In the cytoplasm and in the absence of SHH, Gli usually forms a complex with several regulatory protein kinases, e.g. Fused (Fu), Suppressor of Fused (Sufu) and others like protein kinase A (PKA), glycogen synthase kinase 3 (GSK3) or casein kinase 1 (CK1) [31], indicating that Gli

**Fig. 4.** Kaplan-Meier curves were performed to investigate the patient survival. 

**A** Patient survival rates depending on grading. 

**B** Patient survival rates depending on expression of Ptc at the tumor center in cases with grade 2 pancreatic cancer. 

**C** Patient survival rates depending on expression of PDX-1 at the tumor front in cases with grade 3 pancreatic cancer.
has more functions in pancreatic carcinogenesis than just mediating the hedgehog signaling pathway [for a detailed review, see [14]]. Our results show an overall low activity of the SHH pathway, especially in the tumor center, which explains the predominant cytoplasmic staining of Gli-1 in these cases. During embryonic development, SHH repression in the foregut endoderm leads to the activation of the homeobox transcription factor PDX-1 in the pancreatic bud [32]. While PDX-1 expression is restricted to β-cells in the normal adult pancreas, reactivation can occur by inflammation, regeneration and tumor formation already in early precursor lesions like PanIN [33]. Several studies have shown that PDX-1 is expressed in up to 50% of pancreatic ductal adenocarcinomas and correlated with staging, lymph node status, proliferation index and prognosis [34, 35]. Although a nuclear expression of the transcription factor PDX-1 has been repeatedly demonstrated in pancreatic β-cells, we and others found a predominant cytoplasmic localization in the investigated pancreatic ductal adenocarcinomas. In endocrine cells, the nucleo-cytoplasmatic translocation of PDX-1 has been shown to be regulated by glucose metabolism, oxidative stress and subsequent activation of the c-Jun N-terminal kinase (JNK) pathway [36, 37]. Interestingly, gemcitabine, which was included in the standard chemotherapy regimen of our patients, has been shown to induce apoptosis also via the JNK pathway [38, 39] and may thus contribute to the cytoplasmic localization of PDX-1 found in our study. Other factors regulating the nuclear translocation of PDX-1 include signaling through phosphatidylinositol 3-kinase (PI3K) [40, 41] or posttranscriptional modifications as ubiquitination or sumoylation [42], which have not yet been confirmed in clinical specimens of pancreatic ductal adenocarcinoma. We previously identified two major morphologic and molecular pathways in human pancreatic cancer cell lines using xenograft models: A ductal tumor pattern with predominance of CK7 and PDX-1 and a more differentiated solid tumor pattern with increased expression of CK8 and SHH/Ptc [43]. As our patients were treated for invasive ductal adenocarcinoma, we expected and confirmed a ductal morphology with low levels of SHH but with higher levels of PDX-1. Additionally, the expression levels of hedgehog proteins like SHH, Ptc and Gli-1 was reduced under preoperative chemotherapy as in our epigenetic studies, indicating the relevance of analyzing the expression pattern of these embryonic markers for further therapeutic interventions [44]. Looking in detail at tumor compartments, previous studies have shown that proliferation, which occurs predominantly at the tumor front, is dependent on SHH expression in pancreas cancer [35]. In vitro experiments demonstrated that down-regulation of the hedgehog pathway through siRNA or cyclopamine is essentially associated with a strongly reduced proliferation activity [17, 45]. These observations were made in other types of human cancer as well. In colorectal adenocarcinoma, SHH and the expression of its downstream signaling components Gli-1 and FOXM1 were markedly increased compared to normal colonic tissue [46]. The same findings could be confirmed in the colon adenocarcinoma-derived cell line HT-29: Here, exogenous SHH stimulation increased proliferation and was abrogated by treatment with cyclopamine or specific anti-SHH-antibodies. This further exemplifies that a subset of cells (i.e. SHH-positive cells) at the tumor front might be responsible for proliferation and invasion of the tumor and possesses early developmental or stem-cell-like properties [47]. Another study identified a subtype of cells in pancreatic cancer termed ‘pancreatic cancer stem cells’ for their ability of self-renewal, of producing differentiated progeny and increased expression of the developmental signaling molecule SHH, properties usually shared with stem cells [48]. These findings suggest that the capability of a tumor to grow and propagate is dependent on this stem-cell-like subtype within the tumor itself. The number of these subsets of cells, which are positive for the surface markers CD44, CD24 and ESA is quantified at 0.2–0.8% of the total pancreatic cancer cells. SHH expression in this subset of cells was upregulated 46-fold compared to normal pancreatic epithelial cells, while SHH expression in bulk pancreatic cancer cells was upregulated 4-fold compared to normal pancreatic epithelial cells. It is therefore possible that the increased expression of SHH at only some cells at the tumor front in our samples could be attributed to this subset of pancreatic cancer cells. Using microarray investigations, it was shown that the gene and protein expression pattern depends significantly on the localization inside pancreatic cancer [49]. Our results showed that a higher proliferation index (determined by Ki-67 immunohistochemistry) is found at the tumor front and in chemotherapy-naive specimens and that Ki-67 is strongly associated with PDX-1 expression at this location. Our results thus confirm findings in ovarian carcinomas showing a positive association between cell proliferation (as measured by Ki-67 positivity) in vivo and embryonic marker gene expression [50]. Interestingly, p53 expression was also associated with Ki-67 expression at both sites and with both PDX-1 and Gli-1 only at the tumor center. These findings indicate differential roles of p53 during pancreatic cancer
formation and progression; further studies are needed to address this issue.

Our findings show a differential association of the investigated markers with the patients’ clinico-pathological features. While nodal-negative cases are associated with PDX-1, nodal-positive cases are linked to Ptc and Gli-1 expression, indicating that different molecular mechanisms of embryonic markers are involved in the development of nodal metastasis. Interestingly, another investigation found a completely different association of PDX-1 expression and nodal status which could be caused by the heterogeneous patient group (e.g. all UICC stages) as well as by the fact that we analyzed the whole and not the topographical expression pattern inside pancreatic tumors [35]. Using a survival analysis, classical grading was a negative predictor of outcome [18]. Interestingly, after stratification with grading, PDX-1 and Ptc were also predictors of outcome. Especially the negative predictor—PDX-1 is comparable to earlier findings. Koizumi et al. [34] showed that the survival of PDX-1-positive patients was poorer than that of PDX-1-negative patients On the other hand, upregulation of the hedgehog ligand receptor Ptc could be identified as a positive predictive marker of patient outcome and was in line with the study of Liu et al. [51] showing reduced expression in cases with poorly differentiated cancer. Taken together, these findings support that morphologic and molecular patterning inside of the heterogeneous tumor compartments is involved in tumor progression and clinical outcome. Although we investigated a relatively homogeneous group of invasive ductal adenocarcinomas of the pancreas in our study, the findings must be considered with caution considering the small number of patients (especially of pretreated cases), which limits the power of our study. Additional prospective studies are needed to confirm our findings and establish these embryonic marker genes as potential new biomarkers of pancreatic cancer.

Acknowledgements

The excellent technical assistance of Andrea Hartl and Sandra Leitner is gratefully acknowledged. This work was supported by a grant of the Johannes and Frieda Marohn-Foundation.

References


